Risk of tuberculosis from arthritis medication examined
Treatment with anti-tumour necrosis factor (TNF) agents is recognised as a risk factor for tuberculosis (TB) in patients with immune-mediated inflammatory diseases such as rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, psoriatic arthritis and psoriasis. Most TB cases develop as a result of reactivation of a latent TB infection, and health authorities worldwide recommend screening for latent TB and treating patients before initiating anti-TNF treatment. A new study examined cases of TB associated with anti-TNF therapy and found that the risk of TB is higher for patients receiving anti-TNF monoclonal antibody therapy (infliximab or adalimumab) than for those receiving soluble TNF receptor therapy (etanercept). The study is published in the July issue of Arthritis and Rheumatism...
Read the whole article on Science Centric
More from Science Centric
Related
- Risk of tuberculosis from arthritis medication examinedTue, 30 Jun 2009, 18:42:30 EDT
- Adalimumab therapy effective in AS, RA and PsA patients refractory to other anti-TNF therapiesThu, 12 Jun 2008, 10:36:26 EDT
- New drug shows promising results for psoriatic arthritisTue, 7 Apr 2009, 13:29:37 EDT
- Anti-tumor necrosis factor treatment does not increase cancer Risk in RA patientsThu, 29 Oct 2009, 1:23:53 EDT
- Defining the link between anti-TNF therapies and increased tuberculosisTue, 21 Apr 2009, 8:58:28 EDT